港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

抗疫概念

879.051

+0.5640.06%

漲家數：8

跌家數：9

平家數：- -

市盈率：- -

高：884.571

開：878.433

低：868.104

收：878.487

成交量：1.57億

成交額：11.03億

市值：5,941.35億

流通市值：4,919.55億

資料載入中...

總覽新聞資訊

港股異動 | 復星醫藥(02196.HK)早盤升逾5% 控股子公司279.96億印度盧比出售Gland Pharma約6.00%股權

禮邦醫藥-B公布H股獲納入港股通及恒生綜合指數

開拓藥業-B(09939.HK)：KT-939人體長期安全性試驗順利完成

2026年國家醫保談判在北京啓動；珍視明回應滴眼液抽檢不合格事件 | 醫藥早參

每日经济新闻

港股概念追蹤 | 創新藥賽道持續升温 AI提效向臨床縱深推進(附概念股)

復星醫藥(02196.HK)擬回購不超過10億港元H股

復星醫藥：擬12個月內回購不超過10億港元H股

南方财经网

復星醫藥(600196.SH)控股子公司擬出售Gland Pharma部分股權

迪哲醫藥高管發布減持計劃後，股價下跌超5%！公司回應：對長期發展充滿信心

每日经济新闻

銷量暴漲371%，中國車企卻在歐洲被經銷商追欠款半年

禮邦醫藥-B(09637)H股獲納入港股通及恒生綜合指數

中國中藥(00570)：1.1類中藥創新藥醒脾解鬱片獲批上市

君實生物：公司將於9月14日召開2026年半年度業績説明會

证券日报网

上交所宣佈調整滬港通下港股通標的，調入百度、歌禮制藥等54只，調出佑駕創新等15只。

復星醫藥(02196.HK)獲控股股東復星高科技質押3.3億股A股

復星醫藥：復星高科技質押3.30億股用於償還債務

南方财经网

交銀國際：創新持續驅動醫藥高增長承壓板塊邊際改善盈利預期更趨樂觀

同源康醫藥－Ｂ(02410)股價上升5.029%，現價港幣$6.37

阿斯达克财经

大行評級丨星展：上調比亞迪電子目標價至40港元，維持「買入」評級

港股異動 | 四環醫藥(00460)午前漲近4% 軒竹生物與INNOBIC就吡洛西利於泰國市場達成商業化合作

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/BK1515/news?page=9"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"BK1515","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","market":"HK","secType":"PLATE","nameCN":"抗疫概念","latestPrice":879.05084,"timestamp":1789624615879,"preClose":878.48724,"halted":0,"volume":156800686,"delay":0,"changeRate":0.000642,"floatShares":0,"shares":0,"eps":0,"marketStatus":"交易中","change":0.563599,"latestTime":"09-17 13:56:56","open":878.4325,"high":884.57117,"low":868.10425,"amount":1102813896,"amplitude":0.018745,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1789632600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789608600000,1789617600000],[1789621200000,1789632000000]],"pbRate":1.317311,"peRate":17.071131,"turnoverRate":0.002148,"increases":8,"decrements":9,"flats":0,"marketCap":594134711296,"floatMarketCap":491955452736},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","high":884.57117,"amplitude":0.018745,"preClose":878.48724,"low":868.10425,"pbRate":"1.317311","latestPrice":879.05084,"volume":156800686,"delay":0,"open":878.4325,"prevYearClose":1190.107,"prevWeekClose":878.789,"prevMonthClose":925.265,"prevQuarterClose":802.777,"fiveDayClose":890.408,"twentyDayClose":941.274,"sixtyDayClose":813.549,"secType":"PLATE","market":"HK","turnoverRate":0.002148,"peRate":17.071131,"marketCap":594134711296,"floatMarketCap":491955452736,"timestamp":1789624615879,"nameCN":"抗疫概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1515\",,,,undefined,":{"bkCode":"BK1515","up":8,"down":9,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1515\",pageSize:20,pageCount:9,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2665935403","title":"港股異動 | 復星醫藥(02196.HK)早盤升逾5% 控股子公司279.96億印度盧比出售Gland Pharma約6.00%股權","url":"https://stock-news.laohu8.com/highlight/detail?id=2665935403","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665935403?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 09:35","pubTimestamp":1788744909,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02196","BK1191","BK1593","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665398982","title":"禮邦醫藥-B公布H股獲納入港股通及恒生綜合指數","url":"https://stock-news.laohu8.com/highlight/detail?id=2665398982","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665398982?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 08:50","pubTimestamp":1788742200,"startTime":"0","endTime":"0","summary":"模拟交易客户端礼邦医药-B公布，据港股通的相关安排及调整，公司H股获纳入港股通合资格证券名单，将自2026年9月7日（星期一）起生效。H股获纳入港股通乃基于其获纳入恒生综合指数。董事会认为，H股获纳入港股通及恒生综合指数，反映了资本市场对公司价值及长期发展前景的认可，并将有助于进一步扩大公司的投资者基础，提升H股的交易流动性。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-09-07/doc-iniqyeua9585261.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1515","BK1161","09637","BK1191","BK1574","HSCI","159938","FLHK","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665601053","title":"開拓藥業-B(09939.HK)：KT-939人體長期安全性試驗順利完成","url":"https://stock-news.laohu8.com/highlight/detail?id=2665601053","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665601053?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 08:01","pubTimestamp":1788739288,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09939","BK1161","BK1574","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665367071","title":"2026年國家醫保談判在北京啓動；珍視明回應滴眼液抽檢不合格事件 | 醫藥早參","url":"https://stock-news.laohu8.com/highlight/detail?id=2665367071","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665367071?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 07:01","pubTimestamp":1788735712,"startTime":"0","endTime":"0","summary":"丨2026年9月7日星期一丨NO.12026年国家医保谈判在北京启动9月5日，2026年国家医保目录谈判竞价和商保创新药目录价格协商在北京启动，预计持续4至5天。新版目录有望于11月底前公布，2027年1月1日起执行。与往年相比，今年国谈整体提前约一个月，已有59个创新药完成参考药预沟通，并新增创新药“预申报”。点评：预沟通与预申报缩短创新药准入周期，有利于药企加快商业化节奏。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609073866183218.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609073866183218.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","APXH","09939","XLVI","PBPH","BMED","BK1574","BK1515","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665836774","title":"港股概念追蹤 | 創新藥賽道持續升温 AI提效向臨床縱深推進(附概念股)","url":"https://stock-news.laohu8.com/highlight/detail?id=2665836774","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665836774?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 06:53","pubTimestamp":1788735233,"startTime":"0","endTime":"0","summary":"西湖大学生命科学学院教授黄晶表示，AI辅助新药研发已不止于概念，而真正可以支撑原创药物从发现走向临床，直至上市。艾普司韦是西湖大学首款完全自主研发的1类创新药，用于成人轻型、中型新型冠状病毒感染的治疗。中国AI制药市场规模2025年已突破6亿元。从经营数据来看，AI相关业务正成为部分企业订单和收入增长的重要驱动力；与此同时，下游药企也在积极拥抱AI，研发提效成果逐步显现。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492510.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","BK1617","BK1191","IBBQ","BK1161","AGIX","02196","LNGR","ARTY","06978","AIPO","CHAT","BK1141","VTHR","BK4585","BK1515","QTOC","03696","KCAI","BK4588","VXUS","MEDX","BK1593","02228","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665517364","title":"復星醫藥(02196.HK)擬回購不超過10億港元H股","url":"https://stock-news.laohu8.com/highlight/detail?id=2665517364","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665517364?lang=zh_tw&edition=fundamental","pubTime":"2026-09-06 18:25","pubTimestamp":1788690331,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1515","BK1593","02196","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665364975","title":"復星醫藥：擬12個月內回購不超過10億港元H股","url":"https://stock-news.laohu8.com/highlight/detail?id=2665364975","media":"南方财经网","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665364975?lang=zh_tw&edition=fundamental","pubTime":"2026-09-06 18:12","pubTimestamp":1788689520,"startTime":"0","endTime":"0","summary":"南财智讯9月6日电，复星医药（02196.HK）发布自愿公告，基于对集团发展前景的信心及内在价值的认可，经董事会批准，公司拟自2026年8月27日起12个月内回购H股，回购资金总额不超过10亿港元。本次回购依据2026年6月16日股东周年大会、H股类别股东会及A股类别股东会授予董事会的H股回购一般性授权实施。回购H股用途包括注销或作为库存股份持有。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609063866106963.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609063866106963.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0096","BK0196","BK0187","02196","BK1515","BK1593","BK0175","BK0028","BK0188","BK0012","BK1191","600196","BK0239","BK0183","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665361715","title":"復星醫藥(600196.SH)控股子公司擬出售Gland Pharma部分股權","url":"https://stock-news.laohu8.com/highlight/detail?id=2665361715","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665361715?lang=zh_tw&edition=fundamental","pubTime":"2026-09-06 17:00","pubTimestamp":1788685207,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，印度时间2026年9月4日，公司控股子公司复星医药新加坡公司通过大宗交易及集中竞价方式出售共计989.70万股 Gland Pharma 股份，交易总对价为279.96亿印度卢比，均价约为2,828.78印度卢比/股、较前一交易日收盘价格折让约2.72%。紧随本次交易完成后，集团仍持有 Gland Pharma 约45.76%的股权、为其控股股东，Gland Pharma 仍为集团合并报表范围内子公司。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492481.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK0096","BK0175","BK0012","BK0188","BK0060","BK0187","BK0183","BK0196","BK1515","600196","02196","BK0239","BK0028","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665361549","title":"迪哲醫藥高管發布減持計劃後，股價下跌超5%！公司回應：對長期發展充滿信心","url":"https://stock-news.laohu8.com/highlight/detail?id=2665361549","media":"每日经济新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665361549?lang=zh_tw&edition=fundamental","pubTime":"2026-09-06 14:57","pubTimestamp":1788677820,"startTime":"0","endTime":"0","summary":"迪哲医药对每经记者表示，公司始终认为，上市公司股价的长期走势根本上取决于基本面和经营实绩，并对长期发展充满信心。2026年8月至今，迪哲医药自愿披露多份利好公告。2026年9月3日盘后，迪哲医药发布了关于董事、高级管理人员减持股份计划公告。在发布高管减持计划后的首个交易日，迪哲医药股价表现不佳，盘中跌幅一度超过6%，收盘下跌5.01%。截至9月4日，迪哲医药收盘价报57.01元，市值约为265.5亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-09-06/doc-iniqwnma6518378.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-09-06/doc-iniqwnma6518378.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","BK1161","BK1515","159938","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665361021","title":"銷量暴漲371%，中國車企卻在歐洲被經銷商追欠款半年","url":"https://stock-news.laohu8.com/highlight/detail?id=2665361021","media":"虎嗅APP","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665361021?lang=zh_tw&edition=fundamental","pubTime":"2026-09-06 11:06","pubTimestamp":1788663960,"startTime":"0","endTime":"0","summary":"相关报道称，多位德国经销商向媒体控诉，小鹏和比亚迪的付款周期长达半年以上，单店欠款普遍达到六位数欧元。对此，小鹏汽车方面公开表态确认存在延迟，但否认有任何故意拖延的意图。有经销商直言，中国车企对经销商“并非完全信任”，以至于层层设防，部分审批还要上报中国总部。其次，欧洲汽车经销合同有明确的行业惯例。一旦中国车企的付款行为被认定为“不公平商业行为”，车企可能面临法律诉讼和行业制裁。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MTQzMjE1NjQwMQ==&mid=2656200882&idx=2&sn=0187d8ceb8697f8fd5423a7ce15f69c7&chksm=67d904921b128560a56d737aec95ac17fc9a35669e8947fc481442c669e730fa119f2dcca557&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["SG9999015945.SGD","EVS.SI","IE00BZ08YS42.EUR","LU0509642566.USD","LU0029874905.USD","BK0188","09868","LU0348805143.USD","LU0572944931.SGD","81211","LU0143863784.USD","LU0327786744.USD","LU0605514214.HKD","LU0823426480.USD","FDRV","LU1961090484.USD","LU0359201885.HKD","LU1880383440.USD","LU0269904917.USD","LU1328277881.USD","BK1149","LU1770034418.SGD","BK1515","LU0289960550.SGD","LU1303224171.USD","LU1242518931.SGD","XPEV","LU0823038988.USD","SMOG","BK1589","LU1868838027.USD","HYDD.SI","LU2778985437.USD","BYDDY","XPEG","002594","LU0463099449.HKD","LU1023057109.AUD","LU0593848301.USD","LU1997245177.USD","LU0214875030.USD","SG9999015952.SGD","LU0348735423.USD","LU2449936058.SGD","LU1580142542.USD","BK1539","LU1242518857.USD","BK0169","01211","00285"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664332059","title":"禮邦醫藥-B(09637)H股獲納入港股通及恒生綜合指數","url":"https://stock-news.laohu8.com/highlight/detail?id=2664332059","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664332059?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 21:34","pubTimestamp":1788528840,"startTime":"0","endTime":"0","summary":"H股获纳入港股通乃基于其获纳入恒生综合指数。根据恒生指数有限公司于2026 年8月21日公布的截至2026年6月30日的恒生指数系列季度检讨结果，H股获纳入恒生综合指数成份股，有关变动已于2026年9月4日(星期五)收市后实施，并将自 2026年9月7日(星期一)起生效。董事会认为，H股获纳入港股通及恒生综合指数，反映了资本市场对公司价值及长期发展前景的认可，并将有助于进一步扩大公司的投资者基础，提升H股的交易流动性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492382.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HSCI","09637","BK1191","BK1515","FLHK","BK1161","BK1574","09939","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664334496","title":"中國中藥(00570)：1.1類中藥創新藥醒脾解鬱片獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2664334496","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664334496?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 20:50","pubTimestamp":1788526251,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国中药(00570)发布公告，有关国家药监局受理集团的附属公司国药集团同济堂（贵州）制药有限公司（同济堂制药）的1.1类中药创新药郁枢达片注册上市申请。经国家药监局完成技术审评、现场核查、抽样检验等一系列工作程序，同济堂制药申报的1.1类中药创新药醒脾解郁片（即先前公告所称“郁枢达片”，为该药品获国家药监局核准的规范通用名称）已获得批准上市，药品上市许可持有人为同济堂制药。醒脾解郁片具有醒脾化湿、理气解郁的功效，用于轻、中度抑郁症，症状为情绪郁闷、低落，表情淡漠、倦怠乏力、失眠多梦、少气懒言、食少纳呆，头重肢困、 口中黏腻、面色晦暗，舌淡苔白腻或灰腻、脉滑或弦。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492351.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","BK1515","BK1606","IBBQ","BK1161","00570","LNGR","MEDX","BK1574","BK1191","IPOS","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664733252","title":"君實生物：公司將於9月14日召開2026年半年度業績説明會","url":"https://stock-news.laohu8.com/highlight/detail?id=2664733252","media":"证券日报网","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664733252?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 20:32","pubTimestamp":1788525120,"startTime":"0","endTime":"0","summary":"证券日报网讯9月4日，君实生物发布公告称，公司计划于2026年9月14日10：00-11：00举行2026年半年度业绩说明会。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-04/doc-iniqskus1210060.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-04/doc-iniqskus1210060.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1583","BK1161","BK1515","01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664233915","title":"上交所宣佈調整滬港通下港股通標的，調入百度、歌禮制藥等54只，調出佑駕創新等15只。","url":"https://stock-news.laohu8.com/highlight/detail?id=2664233915","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664233915?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 19:33","pubTimestamp":1788521612,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0052750758.USD","LU0287142896.SGD","LU1328615791.USD","BK1144","LU0043850808.USD","BK1588","SG9999014674.SGD","89888","LU0640798160.USD","LU0359201885.HKD","LU0417516902.SGD","LU0630378429.USD","LU0531971595.HKD","LU0463099449.HKD","HK0000306701.USD","BK1609","LU0197773160.USD","LU0173614495.USD","TCHI","LU0871576103.HKD","LU0762541174.USD","LU0315179316.USD","LU0228367735.SGD","LU0326950275.SGD","LU1188198961.HKD","LU0359202008.SGD","09888","LU0307460666.USD","BIDU","LU0163747925.USD","LU0762542818.HKD","HK0000320264.USD","LU1023057109.AUD","LU0149721374.USD","LU0856984785.SGD","LU1048596156.SGD","LU2476274308.USD","LU0348735423.USD","LU0417516738.SGD","01672","IE0034224299.USD","LU0359201612.USD","LU0348825331.USD","LU0831093199.SGD","LU2778985437.USD","LU0819121731.USD","HK0000320223.HKD","BK1574","LU0456827905.SGD","LU0164880469.USD","LU1048588211.SGD","LU0588546209.SGD","BK1615","LU0320764599.SGD","LU1481107354.HKD","LU0708995583.HKD","HK0000306685.HKD","BK1587","LU0051755006.USD","SG9999002828.SGD","LU0821914370.USD","LU0244354667.USD","LU0823426308.USD","LU0197773673.USD","BK1575","LU0039217434.USD","LU0823426480.USD","LU0543330566.HKD","02431","LU0072462343.USD","LU2039709279.SGD","BK1515","LU0164865239.USD","LU0630378692.HKD","BK1095","LU1115378108.SGD","BK1161","LU1831875114.USD","IE00B3M56506.USD","LU0762540952.USD","SG9999002463.SGD","LU0229945570.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664338732","title":"復星醫藥(02196.HK)獲控股股東復星高科技質押3.3億股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2664338732","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664338732?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 17:26","pubTimestamp":1788513984,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1593","83130","BK1147","83188","03188","82846","02846","02196","03130","BK1191","BK1515","07233","02827"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664840380","title":"復星醫藥：復星高科技質押3.30億股用於償還債務","url":"https://stock-news.laohu8.com/highlight/detail?id=2664840380","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664840380?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 16:25","pubTimestamp":1788510357,"startTime":"0","endTime":"0","summary":"南财智讯9月4日电，复星医药公告，公司控股股东上海复星高科技(集团)有限公司于2026年9月3日将其持有的330000000股A股股份办理质押，占其所持股份比例34.32%，占公司总股本比例12.36%，质押用途为偿还债务。本次质押后，复星高科技累计质押股份数量为696275000股，占公司总股本26.07%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609043865437383.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609043865437383.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1593","02196","BK0028","BK0096","BK0183","BK0012","BK0187","BK1191","BK0196","600196","BK1515","BK0239","BK0188","BK0175","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664382826","title":"交銀國際：創新持續驅動醫藥高增長 承壓板塊邊際改善 盈利預期更趨樂觀","url":"https://stock-news.laohu8.com/highlight/detail?id=2664382826","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664382826?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 14:50","pubTimestamp":1788504630,"startTime":"0","endTime":"0","summary":"创新药产业链增速领跑行业，服务板块复苏在各子板块中，创新产业链继续领跑行业：1)港股/A 股CXO 收入整体增长29.2%/25.3%，(扣非)净利润增长23.4%/67.6%，在各子板块中增速领先，汇率波动对表观利润率有一定压力，但行业整体景气度和订单需求处于高位。其中生物药增速远超化药，在板块收入中的占比也进一步提升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491999.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1574","09939","159938","03329","BK1147","ZECP","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664381726","title":"同源康醫藥－Ｂ(02410)股價上升5.029%，現價港幣$6.37","url":"https://stock-news.laohu8.com/highlight/detail?id=2664381726","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664381726?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 14:05","pubTimestamp":1788501900,"startTime":"0","endTime":"0","summary":"[上升股]同源康医药－Ｂ(02410) 股价在下午02:05比前收市价上升5.029%，现股价为港币$6.37。至目前为止，今日最高价为$6.37，而最低价为$6.065。总成交量为410.589万股，总成交金额为港币$2.551千万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152547499_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152547499_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2609046129/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2609046129/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["09939","BK1161","159938","BK1574","BK1515","02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664038995","title":"大行評級丨星展：上調比亞迪電子目標價至40港元，維持「買入」評級","url":"https://stock-news.laohu8.com/highlight/detail?id=2664038995","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664038995?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 13:14","pubTimestamp":1788498884,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1149","BK1540","BK1167","LU0348767384.USD","BK1607","BK1515","LU0274383008.USD","BK1504","BK1582","BK1580","00285","BK1589","LU0348766576.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664386607","title":"港股異動 | 四環醫藥(00460)午前漲近4% 軒竹生物與INNOBIC就吡洛西利於泰國市場達成商業化合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2664386607","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664386607?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 11:52","pubTimestamp":1788493955,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，四环医药午前涨近4%，截至发稿，涨3.92%，报0.795港元，成交额981.3万港元。Innobic(亚洲)将作为经销商，负责目标产品于目标区域的药品注册、本地市场营销及商业化运营。轩竹生物将按约定供货价格供应目标产品，以支持目标产品在目标区域的商业化活动。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491955.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00460","BK1191","BK4585","BK1600","VXUS","BK1515","BK1593","BK4588","KCAI","02575"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":200,"code":"91000000","status":"200"}]}}